Immunoglobulin G galactosylation levels are decreased in systemic sclerosis patients and differ according to disease subclassification

References

• Korman B, Marangoni RG, Lord G, Olefsky J, Tourtellotte W, Varga J. Adipocyte-specific repression of PPAR-gamma by NCoR contributes to scleroderma skin fibrosis. Arthritis Res Ther 2018;20:145.
   PubMed Web of Science ®Google Scholar
• Dilia G, Michele C, Emanuele C, Amelia S, Federica L, Clodoveo F. From localized scleroderma to systemic sclerosis: coexistence or possible evolution. Dermatol Res Pract 2018;2018:1284687.
   PubMedGoogle Scholar
• Silva BRA, Rodrigues RS, Rufino R, Costa CH, Vilela VS, Levy RA, et al. Computed tomography trachea volumetry in patients with scleroderma: association with clinical and functional findings. PLoS One 2018;13:e0200754.
   PubMed Web of Science ®Google Scholar
• Bunn CC, Black CM. Systemic sclerosis: an autoantibody mosaic. Clin Exp Immunol 1999;117:207–8.
   PubMed Web of Science ®Google Scholar
• Patterson KA, Roberts-Thomson PJ, Lester S, Tan JA, Hakendorf P, Rischmueller M, et al. Interpretation of an extended autoantibody profile in a well-characterized Australian systemic sclerosis (scleroderma) cohort using principal components analysis. Arthritis Rheumatol 2015;67:3234–44.
   PubMed Web of Science ®Google Scholar
• Nikpour M, Baron M. Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies. Curr Opin Rheumatol 2014;26:131–7.
   PubMed Web of Science ®Google Scholar
• Florez-Pollack S, Kunzler E, Jacobe HT. Morphea: current concepts. Clin Dermatol 2018;36:475–86.
   PubMed Web of Science ®Google Scholar
• Dekkers G, Rispens T, Vidarsson G. Novel concepts of altered immunoglobulin G galactosylation in autoimmune diseases. Front Immunol 2018;9:553.
   PubMed Web of Science ®Google Scholar
• Peschke B, Keller CW, Weber P, Quast I, Lunemann JD. Fc-galactosylation of human immunoglobulin gamma isotypes improves C1q binding and enhances complement-dependent cytotoxicity. Front Immunol 2017;8:646.
   PubMed Web of Science ®Google Scholar
• Karsten CM, Pandey MK, Figge J, Kilchenstein R, Taylor PR, Rosas M, et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1. Nat Med 2012;18:1401–6.
   PubMed Web of Science ®Google Scholar
• Saggu G, Okubo K, Chen Y, Vattepu R, Tsuboi N, Rosetti F, et al. Cis interaction between sialylated FcgammaRIIA and the alphaI-domain of Mac-1 limits antibody-mediated neutrophil recruitment. Nat Commun 2018;9:5058.
   PubMed Web of Science ®Google Scholar
• Kronimus Y, Dodel R, Galuska SP, Neumann S. IgG Fc N-glycosylation: alterations in neurologic diseases and potential therapeutic target? J Autoimmun 2019;96:14–23.
   PubMed Web of Science ®Google Scholar
• van de Bovenkamp FS, Hafkenscheid L, Rispens T, Rombouts Y. The emerging importance of IgG Fab glycosylation in immunity. J Immunol 2016;196:1435–41.
   PubMed Web of Science ®Google Scholar
• Sabouri Z, Schofield P, Horikawa K, Spierings E, Kipling D, Randall KL, et al. Redemption of autoantibodies on anergic B cells by variable-region glycosylation and mutation away from self-reactivity. Proc Natl Acad Sci U S A 2014;111:E2567–75.
   PubMed Web of Science ®Google Scholar
• Canellada A, Gentile T, Dokmetjian J, Margni RA. Occurrence, properties, and function of asymmetric IgG molecules isolated from non-immune sera. Immunol Invest 2002;31:107–20.
   PubMed Web of Science ®Google Scholar
• Ren S, Zhang Z, Xu C, Guo L, Lu R, Sun Y, et al. Distribution of IgG galactosylation as a promising biomarker for cancer screening in multiple cancer types. Cell Res 2016;26:963–6.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhu Q, Han J, Zhang H, Li Y, Ma Y, et al. IgG galactosylation status combined with MYOM2-rs2294066 precisely predicts anti-TNF response in ankylosing spondylitis. Mol Med 2019;25:25.
   PubMed Web of Science ®Google Scholar
• Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 1985;316:452–7.
   PubMed Web of Science ®Google Scholar
• Pasek M, Duk M, Podbielska M, Sokolik R, Szechinski J, Lisowska E, et al. Galactosylation of IgG from rheumatoid arthritis (RA) patients–changes during therapy. Glycoconj J 2006;23:463–71.
   PubMed Web of Science ®Google Scholar
• Shinzaki S, Iijima H, Nakagawa T, Egawa S, Nakajima S, Ishii S, et al. IgG oligosaccharide alterations are a novel diagnostic marker for disease activity and the clinical course of inflammatory bowel disease. Am J Gastroenterol 2008;103:1173–81.
   PubMed Web of Science ®Google Scholar
• Ercan A, Cui J, Chatterton DE, Deane KD, Hazen MM, Brintnell W, et al. Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum 2010;62:2239–48.
   PubMed Web of Science ®Google Scholar
• Gindzienska-Sieskiewicz E, Radziejewska I, Domyslawska I, Klimiuk PA, Sulik A, Rojewska J, et al. Changes of glycosylation of IgG in rheumatoid arthritis patients treated with methotrexate. Adv Med Sci 2016;61:193–7.
   PubMed Web of Science ®Google Scholar
• Yamada K, Ito K, Furukawa J, Nakata J, Alvarez M, Verbeek JS, et al. Galactosylation of IgG1 modulates FcgammaRIIB-mediated inhibition of murine autoimmune hemolytic anemia. J Autoimmun 2013;47:104–10.
   PubMed Web of Science ®Google Scholar
• Ito K, Furukawa J, Yamada K, Tran NL, Shinohara Y, Izui S. Lack of galactosylation enhances the pathogenic activity of IgG1 but Not IgG2a anti-erythrocyte autoantibodies. J Immunol 2014;192:581–8.
   PubMed Web of Science ®Google Scholar
• Qian Y, Wang Y, Zhang X, Zhou L, Zhang Z, Xu J, et al. Quantitative analysis of serum IgG galactosylation assists differential diagnosis of ovarian cancer. J Proteome Res 2013;12:4046–55.
   PubMed Web of Science ®Google Scholar
• van Den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis an American college of rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737–47.
   PubMed Web of Science ®Google Scholar
• Sato S, Ihn H, Kikuchi K, Takehara K. Antihistone antibodies in systemic sclerosis. Association with pulmonary fibrosis. Arthritis Rheum 1994;37:391–4.
   PubMed Web of Science ®Google Scholar
• Nouri S, Jacobe H. Recent developments in diagnosis and assessment of morphea. Curr Rheumatol Rep 2013;15:308.
   PubMed Web of Science ®Google Scholar
• Smith KG, Clatworthy MR. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol 2010;10:328–43.
   PubMed Web of Science ®Google Scholar
• Soma Y, Tamaki T, Kikuchi K, Abe M, Igarashi A, Takehara K, et al. Coexistence of morphea and systemic sclerosis. Dermatology 1993;186:103–5.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Ichiki Y, Kitajima Y. Coexistence of recurrent generalized morphea and systemic sclerosis. Acta Derm Venereol 2009;89:329–30.
   PubMed Web of Science ®Google Scholar
• Rao L, Liu G, Li C, Li Y, Wang Z, Zhou Z, et al. Specificity of anti-SSB as a diagnostic marker for the classification of systemic lupus erythematosus. Exp Ther Med 2013;5:1710–14.
   PubMed Web of Science ®Google Scholar